Plus, a Top 1% analyst weighs in on Wall Street's biggest stock.
Plus, a Top 1% UBS stock picker sees almost 50% upside on this chipmaker, and more.
Plus, the 9th best analyst on Wall Street's favorite AI call, and more.
One stock pick from a top-ranked analyst with an implied upside of 100% or more.
Plus, the latest ticker from a Wall Street analyst with +186% average returns, a Top 1% analyst's take on Tesla, and more.
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
The market may be missing a protein upgrade that favors eggs.
Plus, a firm with three hyperscale leases signed, a biotech with four drugs on market, and a stock down 29% that activists just shook up.
Plus, a chipmaker guiding to 903% earnings growth, a gene therapy stock one top 2% analyst gives 170% upside, and more.
Plus, a quiet winner of the US defense budget, a COVID-era darling due for a resurgence, and a top-tier analyst’s contrarian call carrying more than 100% upside potential.
Plus, a beaten-down enterprise play with more than 100% upside potential, a bitcoin miner with a repositioning plan that caught the eye of a Top 1% analyst, and more.
A below-the-signal beneficiary of the fiber revolution.
Plus, an unexpected beneficiary of a dead deal, a post-AI-selloff dip-buying opportunity, and a high-upside-potential call from an analyst with an average return of more than 80%.
Plus, a beaten-down fintech stock with a favorable risk-reward profile, our Goldman Sachs-backed bull thesis, and Morgan Stanley’s 125% upside data center pick.
Plus, William Blair’s memory “supercycle” winner, a stock Morgan Stanley says has “ongoing execution issues”, Netflix’s new deal, the top IPOs of tomorrow, and more.
Plus, a doubled price target from Aletheia, potential beneficiaries of the latest tariff delay, and much more.
Plus, the mid-cap software stock KeyBanc was wrong about, Goldman Sachs’ semiconductor double-downgrade, and much more.
Plus, dual double-downgrades, a crypto firm with 130% implied upside, and much more.
The secret sauce behind silver’s rally, Wells Fargo’s new pick for AI “super-cycle” leader, Huber Research’s grim view on the Netflix-WBD deal, and much more.
This company could be poised to benefit from one of the most important industrial realignments in the US today.
An income investment for the new rate environment, a massive IPO announcement, an 'overdone' AI selloff, and more.
A beaten-down sector quietly being transformed by AI, a firm 'uniquely positioned' within the Trump administration, and much more.
The energy tail risk no one’s talking about, why a retail giant got double-downgraded, a candidate for the next IPO pop, and more.
